文献速递角膜与眼表疾病

OTX-101滴眼液0.09%治疗干眼病的3期随机双盲研究

A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
PubMed 文献 · Ophthalmology · 2019-04-06

这项3期随机双盲多中心载体对照试验纳入744例干眼病患者,按1:1随机接受OTX-101 0.09%或载体每日两次治疗84天。第84天Schirmer试验评分增加≥10 mm的患眼比例OTX-101组16.6% vs 载体组9.2%(P < 0.001),角膜和结膜染色也显著改善,但全球症状评分两组均较基线降低约30%且组间无显著分离,OTX-101耐受性良好。

要点

  • 第84天Schirmer试验评分增加≥10 mm的患眼比例OTX-101组16.6% vs 载体组9.2%(P < 0.001)。
  • 角膜染色(第28、56、84天)和结膜染色(第56、84天)相对载体显著改善。
  • 全球症状评分两组均较基线降低约30%,但组间无显著分离。

核心结论

  • OTX-101 0.09%治疗干眼病在泪液分泌和眼表完整性方面观察到临床和统计学显著改善。

研究设计与样本

  • 随机、多中心、载体对照、双盲3期临床试验。
  • 纳入18至90岁有干眼病史和临床诊断、全球症状评分≥40(范围0-100)、至少1眼丽丝胺绿结膜染色评分≥3且≤9(范围0-12)的成人患者。
  • 合格患者先进入14至20天导入期,所有患者每日两次给予载体;基线(第0天)仍合格者按1:1随机接受OTX-101 0.09%或载体每日两次治疗84天。
  • 共744例患者随机并接受研究药物(OTX-101 0.09%组371例,载体组373例)。

主要发现

  • 主要终点达到:第84天Schirmer试验评分增加≥10 mm的患眼比例OTX-101 0.09%组16.6% vs 载体组9.2%(P < 0.001)。
  • 角膜染色在第28、56、84天相对载体显著改善。
  • 结膜染色在第56、84天相对载体显著改善。
  • 全球症状评分两组均较基线降低约30%,但组间无显著分离。
  • OTX-101 0.09%耐受性良好,治疗中出现的不良事件主要为轻度。

关键数值与推荐

  • 主要终点为第84天Schirmer试验评分增加≥10 mm的患眼比例。
  • OTX-101 0.09%组第84天Schirmer试验评分增加≥10 mm的患眼比例为16.6%,载体组为9.2%(P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of OTX-101, a novel aqueous nanomicellar formulation of cyclosporine (0.09%), in the treatment of patients with dry eye disease (DED). DESIGN: A randomized, multicenter, vehicle-controlled, double-masked, phase 3 clinical trial. PARTICIPANTS: Adults (18-90 years of age) with a history and clinical diagnosis of DED, a global symptom score of 40 or more (range, 0-100), and a lissamine green conjunctival staining score of 3 or more and 9 or less (range, 0-12) in at least 1 eye. METHODS: Eligible patients entered a run-in period of 14 to 20 days in which all patients administered vehicle twice daily. Patients who remained eligible at the baseline (day 0) visit were randomized in a 1:1 ratio to twice-daily treatment with OTX-101 0.09% or vehicle for 84 days. MAIN OUTCOME MEASURES: Efficacy assessments included signs (unanesthetized Schirmer tear test, corneal and conjunctival staining) and symptoms (global symptom score) of DED. The primary end point was the proportion of eyes with a clinically meaningful improvement (increase of ≥10 mm) in Schirmer test score at day 84. Safety evaluations included adverse events (AEs), visual acuity, and intraocular pressure monitoring, slit-lamp, dilated ophthalmoscopy, and fundus examinations. RESULTS: A total of 744 patients were randomized and received study medication (371 to OTX-101 0.09% and 373 to vehicle). The primary end point was achieved; a significantly greater percentage of eyes in the OTX-101 0.09% treatment group achieved an increase of 10 mm or more in the Schirmer test score at day 84 (OTX-101 0.09%, 16.6%; vehicle, 9.2%; P < 0.001). Significant improvements relative to vehicle also were observed for corneal (days 28, 56, and 84) and conjunctival (days 56 and 84) staining. The global symptom score was reduced from baseline in both treatment groups by approximately 30%; however, no significant separation between groups was observed. The OTX-101 0.09% formulation was well tolerated. Treatment-emergent AEs were primarily mild in intensity. CONCLUSIONS: Clinically and statistically significant improvements in tear production and ocular surface integrity were observed in patients treated with OTX-101 0.09% for DED.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Goldberg DF, Malhotra RP, Schechter BA, et al. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease. Ophthalmology. 2019. PMID: 30965064. doi:10.1016/j.ophtha.2019.03.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。